title: Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).
abstract: OBJECTIVE
  The primary aim of this study was to compare the impact of risperidone long-acting injectable (R-LAI) to other antipsychotics on rates of hospitalisation in real-life settings.
  
  
  METHODS
  The Cohort for the General study of Schizophrenia (CGS) followed 1859 patients diagnosed with schizophrenia (DSM-IV) from 177 psychiatric wards of public and private hospitals across France over a mean period of 12months. These patients were ambulatory or had been hospitalised for less than 93days at study entry. Recruitment was stratified for long-acting second-generation antipsychotic use. A multivariate Poisson regression adjusted for confounding with propensity scores and allowing for autocorrelation was used for the calculation of relative rates of hospitalisation with 95% confidence intervals.
  
  
  RESULTS
  The mean age of participants was 37.65years, 68.3% were male and 36.7% were hospitalised for less than 93days at study entry. Altogether, participants accumulated 796 hospital stays (53.4 per 100 person-years). R-LAI patients were slightly younger and had been hospitalised more often in the past 12months compared to non-R-LAI users. The adjusted Poisson regression analysis showed R-LAI use to be associated with a lower rate of future hospitalisation: 0.66 [0.46-0.96] compared to non-R-LAI use, and 0.53 [0.32-0.88] compared to use of other LAIs.
  
  
  CONCLUSIONS
  Use of R-LAI was associated with lower rates of hospitalisation compared to non-use of R-LAI.
authors: Equipe d'accueil 'Pharmacoépidémiologie et maladies infectieuses', 5 rue du Docteur Roux, 75015 Paris, France.
authors: Lamiae
authors: L
authors: Grimaldi-Bensouda
authors: Frederic
authors: F
authors: Rouillon
authors: Bernard
authors: B
authors: Astruc
authors: Michel
authors: M
authors: Rossignol
authors: Jacques
authors: J
authors: Benichou
authors: Bruno
authors: B
authors: Falissard
authors: Frederic
authors: F
authors: Limosin
authors: Beatrice
authors: B
authors: Beaufils
authors: Guillaume
authors: G
authors: Vaiva
authors: Helene
authors: H
authors: Verdoux
authors: Yola
authors: Y
authors: Moride
authors: Alban
authors: A
authors: Fabre
authors: Florence
authors: F
authors: Thibaut
authors: Lucien
authors: L
authors: Abenhaim
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012044:Regression Analysis; D012189:Retrospective Studies; D018967:Risperidone / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone